| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 09/12/2002 | US20020128279 Potassium channel blocking agents |
| 09/12/2002 | US20020128278 Inhibit some of the ill effects caused by diabetes or by aging; preventing premature aging, rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, atherosclerosis and spoilage of proteins in food |
| 09/12/2002 | US20020128276 Administering an estrogen agonist/ antagonist; lowering vaginal pH; treating an urinary tract infection; treating vaginal dryness, itching, undesired spasms, and vaginitis; treating undesired urinary frequency or incontinence |
| 09/12/2002 | US20020128271 N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| 09/12/2002 | US20020128265 CRF receptor antagonists and methods relating thereto |
| 09/12/2002 | US20020128263 Treatment or prevention of mGluR5 receptor mediated disorders. |
| 09/12/2002 | US20020128247 Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents |
| 09/12/2002 | US20020128240 Treatment of hyperproliferative diseases using active vitamin D analogues |
| 09/12/2002 | US20020128217 Therapeutic use of cis-element decoys in vivo |
| 09/12/2002 | US20020128208 Such as 4-benzoylamino-(2-(2-hydroxyethyl)-piperazin-1-yl-methyl)-phenyl)-benzene -sulfonamide; for treatment of hypertension; treatment of kidney disorders |
| 09/12/2002 | US20020128173 Method of treating or preventing migraine headaches |
| 09/12/2002 | US20020127694 2786, a novel human aminopeptidase |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127612 Cell proliferation polypeptide for use in the diagnosis and treatment of tumors |
| 09/12/2002 | US20020127542 Pharmaceutical compositions for treating tumour diseases |
| 09/12/2002 | US20020127247 Modified clostridial neurotoxins with altered biological persistence |
| 09/12/2002 | CA2440803A1 Modulators of chemokine receptor activity |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440161A1 Inhibitor of monoamine uptake |
| 09/12/2002 | CA2440141A1 Compounds and methods for the treatment of urogenital disorders |
| 09/12/2002 | CA2440038A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439939A1 Novel aminodicarboxylic acid derivatives |
| 09/12/2002 | CA2439934A1 Use of protein histidine phosphatase |
| 09/12/2002 | CA2439849A1 Antagonists of mcp-1 function and methods of use thereof |
| 09/12/2002 | CA2439647A1 Side-chain-halogenated aminodicarboxylic acid derivatives as medicaments for treatment of cardiovascular disorders |
| 09/12/2002 | CA2439594A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438737A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2434184A1 Bisaryl derivatives having fsh receptor modulatory activity |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1238016A1 Substituted phthalocyanines and their precursors |
| 09/11/2002 | EP1237915A2 Polynucleotid encoding the rg1 polypeptide |
| 09/11/2002 | EP1237903A1 11-beta-phenylestradiene derivatives with fluoroalkyl groups in the aromatic side chain, production thereof and pharmaceutical compositions containing these compounds |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237888A2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 09/11/2002 | EP1237887A1 9-(piperazinylalkyl)carbazoles as bax-modulators |
| 09/11/2002 | EP1237886A1 Heterocyclic derivatives |
| 09/11/2002 | EP1237874A2 Selective neurokinin antagonists |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237565A1 Betaglycan as an inhibin receptor and uses thereof |
| 09/11/2002 | EP1237548A1 Il-8 receptor antagonists |
| 09/11/2002 | EP1165122B1 Use of molecular weight-amplified hirudin as an anticoagulant in extracorporeal renal replacement therapy |
| 09/11/2002 | EP0813529B1 Arginine analogues having nitric oxide synthase inhibitor activity |
| 09/11/2002 | EP0668860B1 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses |
| 09/11/2002 | CN1369009A Modified chimeric polyeptides with improved pharmacokinetic properties |
| 09/11/2002 | CN1368960A Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 09/11/2002 | CN1368959A Prostaglandin derivatives |
| 09/11/2002 | CN1368879A Use of (-)(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance type 2 diabetes, hyperlipidemia and hyperuricemia |
| 09/11/2002 | CN1368287A Nano medicine 'Shenfukang' and its preparing process |
| 09/11/2002 | CN1368170A Nano medicine 'Shenshu' and its preparing process |
| 09/11/2002 | CN1368081A Nano medicine 'Qianlieshule' and its preparing process |
| 09/11/2002 | CN1368077A Nano whole eucommia meidicne and its preparing process |
| 09/11/2002 | CN1090617C Pyrole derivatives and medicinal composition |
| 09/11/2002 | CN1090507C Novel pharmaceutical application of nonimmunogenproteinic material and composition |
| 09/11/2002 | CN1090506C Application of lysozyme dimer |
| 09/10/2002 | US6448397 Treating central nervous system diseases with modulation of 5-ht activity; adrenergic, dopaminergic, and serotonergic neurotransmitters; psychosis, paraphrenia, depression, mania, schizophrenia, anxiety, migraine headache, drug addiction |
| 09/10/2002 | US6448285 Disorders associated with overactivity of 5 alpha reductase; androgen dependent disorders such as seborrhoea, acne, hirsutism and/or androgenic alopecia |
| 09/10/2002 | US6448274 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 09/10/2002 | US6448271 Substituted benzimidazoles and their use as parp inhibitors |
| 09/10/2002 | US6448267 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 09/10/2002 | US6448264 Use of 5-thio-, sulfinyl- and sulfonylpyrazolo[3,4-b]-pyridines as cyclin dependent kinase inhibitors |
| 09/10/2002 | US6448254 Substituted amides, their production and their use |
| 09/10/2002 | US6448250 Sulfamato hydroxamic acid metalloprotease inhibitor |
| 09/10/2002 | US6448248 Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists |
| 09/10/2002 | US6448054 Locally administering to a specific site a fugetactic agent in an amount effective to repel immune cells |
| 09/10/2002 | US6448036 ribB |
| 09/10/2002 | US6448011 Isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant adrenergic receptor genes. |
| 09/10/2002 | CA2198562C Method of treating conditions with estrogen agonists |
| 09/08/2002 | CA2370324A1 Large circular target-specific antisense nucleic acid compounds |
| 09/06/2002 | WO2002068461A2 Heterocarpine, a human ghrh-binding protein |
| 09/06/2002 | WO2002068427A1 Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds |
| 09/06/2002 | WO2002068425A1 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists |
| 09/06/2002 | WO2002068419A1 Pyridopyrimidine or naphthyridine derivative |
| 09/06/2002 | WO2002068415A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2002 | WO2002068410A1 Substituted pyrimidinone derivatives as ligands of integrin receptors |
| 09/06/2002 | WO2002068399A1 Aryl carbamate derivatives, preparation and use thereof |
| 09/06/2002 | WO2002068380A1 Synthetic excitatory amino acids |
| 09/06/2002 | WO2002068377A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells |
| 09/06/2002 | WO2002067950A1 Vascular regeneration promoters |
| 09/06/2002 | WO2002067939A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/06/2002 | WO2002067919A1 Il-8 receptor antagonists |
| 09/06/2002 | WO2002067916A2 Pharmaceutical salts |
| 09/06/2002 | WO2002067893A2 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | WO2002067851A2 Method for treating fibrotic diseases or other indications iiic |
| 09/06/2002 | WO2002067651A2 Pharmaceutical salts |
| 09/06/2002 | WO2002043716A3 Method for regulating prostate gland volume with insulin sensitizers |
| 09/06/2002 | WO2002043648A8 Compounds active at the glucocorticoid receptor ii |
| 09/06/2002 | WO2002041882A3 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 09/06/2002 | WO2002040517A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002040037A3 M. tuberculosis chaperonin 60.1 and uses thereof |